Extracellular Vesicle Cargo from Lipofibroblasts Mitigates COPD by Alveolar Type II Cell Restoration - PubMed
6 hours ago
- #Lipofibroblasts
- #COPD
- #Extracellular Vesicles
- Extracellular vesicles (EVs) from lipofibroblasts (LipoFB-EVs) show therapeutic potential for COPD.
- LipoFB-EVs reduce cellular senescence and inflammation in lung epithelial cells by lowering ROS and modulating DNA damage response.
- They exhibit anti-fibrotic effects by inhibiting TGF-β-induced myofibroblast differentiation, outperforming standard anti-fibrotic drugs.
- LipoFB-EVs restore impaired alveolar type 2 (AT2) stem cells, improving their viability, colony formation, and proliferation.
- LipoFB-EVs contain L-type amino acid transporter 1 (LAT1), aiding leucine transport and AT2 cell function restoration.
- In murine COPD models, LipoFB-EVs improved airway inflammation, remodeling, obstruction, senescence, and emphysema.